ArticleThe American journal of managed care2021
340B Drug Pricing Program and hospital provision of uncompensated care.
Article in The American journal of managed care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- The impact of National Volume-Based Procurement (NVBP) on healthcare expenditures for breast cancer outpatients: an interrupted time series analysis in Wuhan, China.BMC health services research · 2025Article
- Variation, Overlap, and Stability in Defining Safety Net Hospitals.JAMA network open · 2025Article
- Local population characteristics and access equity of 340B contract pharmacies.Health affairs scholar · 2025Article
- Expansion of 340B Disproportionate Share Hospitals in the United States From 2010 to 2022.Health services research · 2025Article
- The 340B Program and High-Risk Prescribing of Oral Targeted Therapies for Advanced Prostate Cancer.Urology practice · 2024Article
- 340B Participation and Safety Net Engagement Among Federally Qualified Health Centers.JAMA health forum · 2024Article
- Addressing financial toxicity in cancer treatment-An opportunity for the 340B drug pricing program.Cancer · 2024Article
- Article
- Assessing the Impact of the 340B Drug Pricing Program: A Scoping Review of the Empirical, Peer-Reviewed Literature.The Milbank quarterly · 2024Article
- US Hospital Service Availability and New 340B Program Participation.JAMA health forum · 2024Article
- Characteristics of 340B Hospitals Receiving Medicare Part B Repayments.JAMA health forum · 2024Article
- Outcomes of the 340B Drug Pricing Program: A Scoping Review.JAMA health forum · 2023Article
- Trends in Proportion of Medicare Part D Claims Subject to 340B Discounts, 2013-2020.JAMA health forum · 2023Article
- The impacts of the 340B Program on health care quality for low-income patients.Health services research · 2023Article
- Association Between New 340B Program Participation and Commercial Insurance Spending on Outpatient Biologic Oncology Drugs.JAMA health forum · 2023Article
- Mapping 340B Funds Flow Through Contract Pharmacies.Inquiry : a journal of medical care organization, provision and financingArticle
- The Association of 340B Program Drug Margins with Covered Entity Characteristics.Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectivesTo evaluate whether hospital entry into the 340B Drug Pricing Program, which entitles eligible hospitals to discounts on drug purchases and intends for hospitals to use associated savings to devote more resources to the care of low-income populations, is associated with changes in hospital provision of uncompensated care. STUDY
designWe analyzed secondary data on 340B participation and uncompensated care provision among general acute care hospitals and critical access hospitals from 2003 to 2015. We constructed an annual, hospital-level data set on hospital 340B participation from the Office of Pharmacy Information Systems and on uncompensated care provision from the Hospital Cost Reporting Information System.
methodsFocusing on 2 periods of program expansion, we separately analyzed trends in uncompensated care costs for 340B-eligible general acute care hospitals and critical access hospitals, stratified by year of 340B program entry, including a stratum of eligible hospitals that never participated. We used a differences-in-differences approach to quantify whether there were differential changes in provision of uncompensated care after hospitals enter the 340B program relative to hospitals that did not participate or had not yet entered.
resultsWe do not find evidence that hospitals increased provision of uncompensated care after entry into the 340B program differentially more than hospitals that never entered or had not yet entered the program.
conclusionsRelying on hospitals to invest surplus into care for the underserved without marginal incentives to do so or strong oversight may not be an effective strategy to expand safety-net care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.